According to Ultragenyx's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 8.8773. At the end of 2023 the company had a P/S ratio of 9.04.
Year | P/S ratio | Change |
---|---|---|
2023 | 9.04 | 1.15% |
2022 | 8.94 | -45.19% |
2021 | 16.3 | -51.73% |
2020 | 33.8 | 41.86% |
2019 | 23.8 | -44.54% |
2018 | 42.9 | -94.32% |
2017 | 756 | -96.5% |
2016 | > 1000 | |
2015 | N/A | |
2014 | N/A |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Lexicon Pharmaceuticals
LXRX | > 1000 | 11,339.85% | ๐บ๐ธ USA |
Esperion Therapeutics ESPR | 4.17 | -53.05% | ๐บ๐ธ USA |
Amicus Therapeutics
FOLD | 8.77 | -1.18% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | 6.91 | -22.15% | ๐บ๐ธ USA |